Dixie‐Lee Esseltine
About
Dixie‐Lee Esseltine is a scholar working on Hematology, Molecular Biology and Oncology.
According to data from OpenAlex, Dixie‐Lee Esseltine has authored 38 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Hematology, 27 papers in Molecular Biology and 14 papers in Oncology. Recurrent topics in Dixie‐Lee Esseltine's work include Multiple Myeloma Research and Treatments (35 papers), Protein Degradation and Inhibitors (23 papers) and HIV/AIDS drug development and treatment (7 papers). Dixie‐Lee Esseltine is often cited by papers focused on Multiple Myeloma Research and Treatments (35 papers), Protein Degradation and Inhibitors (23 papers) and HIV/AIDS drug development and treatment (7 papers). Dixie‐Lee Esseltine collaborates with scholars based in United States, United Kingdom and France. Dixie‐Lee Esseltine's co-authors include Paul G. Richardson, David P. Schenkein, Helgi van de Velde, Kenneth C. Anderson, Jean‐Luc Harousseau, Philippe Moreau, William Deraedt, Sundar Jagannath, Melissa Alsina and Rubén Niesvizky and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.
In The Last Decade
Dixie‐Lee Esseltine
38 papers receiving 3.1k citations
Hit Papers
Peers
Dixie‐Lee Esseltine
Ivan Špıčka Czechia
Dan Ayers United States
Klaus Hollmig United States
Mauricio Pineda‐Roman United States
Dixie Esseltine United States
Raymond Powles United Kingdom
K. Martin Kortüm Germany
Tahamtan Ahmadi United States
Jake Shortt Australia
Frederic J. Reu United States
Citations per year, relative to Dixie‐Lee Esseltine Dixie‐Lee Esseltine (= 1×)
peers
Ivan Špıčka
Countries citing papers authored by Dixie‐Lee Esseltine
Since
Specialization
Citations
This map shows the geographic impact of Dixie‐Lee Esseltine's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dixie‐Lee Esseltine with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dixie‐Lee Esseltine more than expected).
Fields of papers citing papers by Dixie‐Lee Esseltine
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Dixie‐Lee Esseltine. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dixie‐Lee Esseltine. The network helps show where Dixie‐Lee Esseltine may publish in the future.
Co-authorship network of co-authors of Dixie‐Lee Esseltine
This figure shows the co-authorship network connecting the top 25 collaborators of Dixie‐Lee Esseltine. A scholar is included among the top collaborators of Dixie‐Lee Esseltine based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dixie‐Lee Esseltine. Dixie‐Lee Esseltine is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Hanley, Michael J., Diane R. Mould, Tim Taylor, et al.. (2017). Population Pharmacokinetic Analysis of Bortezomib in Pediatric Leukemia Patients: Model-Based Support for Body Surface Area-Based Dosing Over the 2- to 16-Year Age Range. The Journal of Clinical Pharmacology. 57(9). 1183–1193.
2.
Tang, Min, Rui Zhao, Helgi van de Velde, et al.. (2016). Myeloma Cell Dynamics in Response to Treatment Supports a Model of Hierarchical Differentiation and Clonal Evolution. Clinical Cancer Research. 22(16). 4206–4214.
3.
Mateos, María‐Victoria, Albert Oriol, Joaquín Martínez‐López, et al.. (2016). Outcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma: matched pair analysis using long-term follow-up data from the phase 3 VISTA and PETHEMA/GEM05 trials. Annals of Hematology. 95(12). 2033–2041.
4.
Leonard, John P., Kathryn S. Kolibaba, James A. Reeves, et al.. (2015). Randomized Phase 2 Open-Label Study of R-CHOP ± Bortezomib in Patients (Pts) with Untreated Non-Germinal Center B-Cell-like (Non-GCB) Subtype Diffuse Large Cell Lymphoma (DLBCL): Results from the Pyramid Trial (NCT00931918). Blood. 126(23). 811–811.
5.
Gupta, Neeraj, et al.. (2014). Switching from body surface area‐based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis. British Journal of Clinical Pharmacology. 79(5). 789–800.
6.
Sonneveld, Pieter, Hartmut Goldschmidt, Laura Rosiñol, et al.. (2013). Bortezomib-Based Versus Nonbortezomib-Based Induction Treatment Before Autologous Stem-Cell Transplantation in Patients With Previously Untreated Multiple Myeloma: A Meta-Analysis of Phase III Randomized, Controlled Trials. Journal of Clinical Oncology. 31(26). 3279–3287.
7.
Esseltine, Dixie‐Lee & George Mulligan. (2012). An Historic Perspective of Proteasome Inhibition. Seminars in Hematology. 49(3). 196–206.
8.
Moreau, Philippe, Vadim Doronin, Alexander Schmidt, et al.. (2012). Pharmacokinetic, Pharmacodynamic and Covariate Analysis of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients with Relapsed Multiple Myeloma. Clinical Pharmacokinetics. 51(12). 823–829.
9.
Moreau, Philippe, Halyna Pylypenko, Sebastian Grosicki, et al.. (2011). Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. The Lancet Oncology. 12(5). 431–440.
10.
Dimopoulos, Meletios Α., María-Victoria Mateos, Paul G. Richardson, et al.. (2010). Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study. European Journal Of Haematology. 86(1). 23–31.
11.
Richardson, Paul G., Edie Weller, Sundar Jagannath, et al.. (2009). Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma. Journal of Clinical Oncology. 27(34). 5713–5719.
12.
Palumbo, Antonio, Rudolf Schlag, Nuriet K. Khuageva, et al.. (2008). Prolonged therapy with bortezomib plus melphalan-prednisone (vmp) results in improved quality and duration of response in the phase iii vista study in previously untreated multiple myeloma (mm). 93. 83–83.
13.
Lonial, Sagar, Paul G. Richardson, Jesús F. San Miguel, et al.. (2008). Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma. British Journal of Haematology. 143(2). 222–229.
14.
Richardson, Paul G., Sundar Jagannath, Andrzej Jakubowiak, et al.. (2008). Lenalidomide, Bortezomib, and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Encouraging Response Rates and Tolerability with Correlation of Outcome and Adverse Cytogenetics in a Phase II Study.. Blood. 112(11). 1742–1742.
15.
Popat, Rakesh, Heather Oakervee, Simon Hallam, et al.. (2008). Bortezomib, doxorubicin and dexamethasone (PAD) front‐line treatment of multiple myeloma: updated results after long‐term follow‐up. British Journal of Haematology. 141(4). 512–516.
16.
Bensinger, William, Sundar Jagannath, Robert Vescio, et al.. (2008). A Phase II Study of Bortezomib (Velcade ®), Cyclophosphamide (Cytoxan®), Thalidomide (Thalomid®) and Dexamethasone as First-Line Therapy for Multiple Myeloma. Blood. 112(11). 94–94.
17.
Faderl, Stefan, R. Kanti, John G. Gribben, et al.. (2006). Phase II study of single‐agent bortezomib for the treatment of patients with fludarabine‐refractory B‐cell chronic lymphocytic leukemia. Cancer. 107(5). 916–924.
18.
Harousseau, Jean‐Luc, Sundar Jagannath, Paul G. Richardson, et al.. (2006). Bortezomib in Combination with High-Dose Dexamethasone (HD dex) and Erythropoietin (EPO) Does Not Result in an Increased Risk of Thromboembolic Complications.. Blood. 108(11). 3543–3543.
19.
Oakervee, Heather, Rakesh Popat, Nicola Curry, et al.. (2005). PAD combination therapy (PS‐341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. British Journal of Haematology. 129(6). 755–762.
20.
Jagannath, Sundar, Bart Barlogie, James R. Berenson, et al.. (2004). A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. British Journal of Haematology. 127(2). 165–172.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Ivan Špıčka Breakdown of academic impact, for papers by Dan Ayers Breakdown of academic impact, for papers by Klaus Hollmig Breakdown of academic impact, for papers by Mauricio Pineda‐Roman Breakdown of academic impact, for papers by Dixie Esseltine Breakdown of academic impact, for papers by Raymond Powles Breakdown of academic impact, for papers by K. Martin Kortüm Breakdown of academic impact, for papers by Tahamtan Ahmadi Breakdown of academic impact, for papers by Jake Shortt Breakdown of academic impact, for papers by Frederic J. Reu